JO3820B1 - أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها - Google Patents

أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Info

Publication number
JO3820B1
JO3820B1 JOP/2013/0131A JOP20130131A JO3820B1 JO 3820 B1 JO3820 B1 JO 3820B1 JO P20130131 A JOP20130131 A JO P20130131A JO 3820 B1 JO3820 B1 JO 3820B1
Authority
JO
Jordan
Prior art keywords
span
rtl
dir
antibodies
fel
Prior art date
Application number
JOP/2013/0131A
Other languages
English (en)
Inventor
Andrew J Murphy
Jamie Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3820(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3820B1 publication Critical patent/JO3820B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتوفير أجسام مضادة ترتبط بمولد حساسية من هرة، </span>Fel d1<span dir="RTL">، وتركيبات تتضمن تلك الاجسام المضادة، وأحماض نووية تشفر الأجسام المضادة وطرق لاستخدام تلك الأجسام المضادة. وفقا لنماذج معينة من الاختراع، تعد الأجسام المضادة عبارة عن أجسام مضادة أحادية النسيلة بشرية كاملة ترتبط بـ </span>Fel d1<span dir="RTL">، تعد الأجسام المضادة وفق الاختراع مفيدة للارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> في الجسم الحي، بما يمنع الارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> بـ </span>IgE<span dir="RTL"> متكون سلفا على سطح الخلايا البدينة أو الخلايا القاعدية. بذلك، تعمل الأجسام المضادة على منع إطلاق الهيستامين والعوامل الوسيطة الالتهابية الأخرى من الخلايا البدينة و/أو الخلايا القاعدية، بما يخفف من استجابة غير مستحبة لمسبب الحساسية من هرة في الأفراد المصابين بالحساسية. يمكن كذلك أن تكون الأجسام المضادة وفق الاختراع مفيدة لأغراض تشخيصية لتحديد ما إن كان المريض حساس لمسبب الحساسية من هرة </span>Fel d1<span dir="RTL">.</span>
JOP/2013/0131A 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها JO3820B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3820B1 true JO3820B1 (ar) 2021-01-31

Family

ID=48326501

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0131A JO3820B1 (ar) 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Country Status (33)

Country Link
US (6) US9079948B2 (ar)
EP (4) EP2844672B1 (ar)
JP (2) JP6400569B2 (ar)
KR (1) KR102185516B1 (ar)
CN (2) CN110240651B (ar)
AR (1) AR090914A1 (ar)
AU (2) AU2013256251C1 (ar)
BR (2) BR122019023685B1 (ar)
CA (1) CA2871077C (ar)
CY (2) CY1124023T1 (ar)
DK (2) DK3978522T3 (ar)
ES (3) ES2780392T3 (ar)
FI (1) FI3978522T3 (ar)
HR (3) HRP20211932T1 (ar)
HU (2) HUE057062T2 (ar)
IL (1) IL235121B (ar)
IN (1) IN2014DN08767A (ar)
JO (1) JO3820B1 (ar)
LT (3) LT3978522T (ar)
MX (2) MX377634B (ar)
MY (3) MY164101A (ar)
NZ (2) NZ733480A (ar)
PL (3) PL3978522T3 (ar)
PT (3) PT2844672T (ar)
RS (3) RS60282B1 (ar)
RU (1) RU2658491C2 (ar)
SG (3) SG10201608378UA (ar)
SI (3) SI3978522T1 (ar)
SM (3) SMT202000241T1 (ar)
TW (2) TW201803901A (ar)
UY (1) UY34782A (ar)
WO (1) WO2013166236A1 (ar)
ZA (3) ZA201407302B (ar)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
EP3036543B1 (en) * 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CN108025059B (zh) * 2015-09-08 2022-09-09 苏黎世大学 抗猫过敏的组合物
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
PL3558347T3 (pl) * 2016-12-22 2026-04-20 Regeneron Pharmaceuticals, Inc. Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi
BR112019015145A2 (pt) * 2017-01-24 2020-03-24 Société des Produits Nestlé S.A. Composições que compreendem anticorpos anti-fel d1 e métodos para reduzir pelo menos um sintoma da alergia de humanos a gatos
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CA3085177A1 (en) 2018-01-31 2019-08-08 Regeneron Pharamaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN119823260A (zh) * 2018-05-18 2025-04-15 陈扎克伯格生物中心旧金山公司 从人中分离过敏原特异性抗体的方法及其用途
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
JP7541534B2 (ja) 2019-05-13 2024-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
KR20260058863A (ko) 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
US20230416349A1 (en) 2022-06-23 2023-12-28 Regeneron Pharmaceuticals, Inc. Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
AU2024229494A1 (en) 2023-03-01 2025-09-11 Regeneron Pharmaceuticals, Inc. Anti-fel d1 antibody formulations
CN121241065A (zh) 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体
JP2026514305A (ja) 2023-05-01 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
EP4780828A2 (en) 2023-09-18 2026-07-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
CN122138969A (zh) 2023-10-18 2026-06-02 瑞泽恩制药公司 从过程中上游细胞培养物材料中快速纯化单克隆抗体
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
TW202600593A (zh) 2024-02-16 2026-01-01 美商再生元醫藥公司 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same
WO2026112457A2 (en) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
WO2026136650A1 (en) 2024-12-20 2026-06-25 Regeneron Pharmaceuticals, Inc. Fixed seed train schedule for improved protein production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
CA2128331A1 (en) * 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2626372B1 (en) * 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ES2635870T3 (es) * 2007-07-09 2017-10-05 Nestec S.A. Métodos para reducir las alergias provocadas por alérgenos ambientales
PL2187964T3 (pl) * 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
PL3558347T3 (pl) 2016-12-22 2026-04-20 Regeneron Pharmaceuticals, Inc. Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi

Also Published As

Publication number Publication date
CN104411719A (zh) 2015-03-11
PT3978522T (pt) 2025-10-17
AU2018203087A1 (en) 2018-05-24
PT2844672T (pt) 2020-04-30
PT3660047T (pt) 2021-11-30
CY1124819T1 (el) 2022-11-25
CN104411719B (zh) 2019-05-14
RS60282B1 (sr) 2020-06-30
US11174305B2 (en) 2021-11-16
RU2014148502A (ru) 2016-06-27
IL235121B (en) 2019-06-30
SG10202102919XA (en) 2021-05-28
US9079948B2 (en) 2015-07-14
MX377634B (es) 2025-03-10
EP2844672B1 (en) 2020-02-12
BR112014026852B1 (pt) 2023-01-03
DK2844672T3 (da) 2020-04-20
NZ701124A (en) 2017-07-28
ZA202005273B (en) 2023-11-29
SI2844672T1 (sl) 2020-07-31
RS67417B1 (sr) 2025-12-31
DK3978522T3 (da) 2025-10-27
JP2015523962A (ja) 2015-08-20
US20160376358A1 (en) 2016-12-29
EP2844672A1 (en) 2015-03-11
MX2020003864A (es) 2020-08-13
TW201803901A (zh) 2018-02-01
HUE057062T2 (hu) 2022-04-28
SI3660047T1 (sl) 2021-12-31
EP3978522A3 (en) 2022-07-06
EP3660047A1 (en) 2020-06-03
US20180305446A1 (en) 2018-10-25
TWI644921B (zh) 2018-12-21
EP4653056A2 (en) 2025-11-26
WO2013166236A1 (en) 2013-11-07
CN110240651A (zh) 2019-09-17
RU2658491C2 (ru) 2018-06-21
CY1124023T1 (el) 2022-03-24
US20130295097A1 (en) 2013-11-07
JP6400569B2 (ja) 2018-10-03
JP2017153491A (ja) 2017-09-07
KR102185516B1 (ko) 2020-12-02
ES2780392T3 (es) 2020-08-25
US9475869B2 (en) 2016-10-25
AR090914A1 (es) 2014-12-17
US10047153B2 (en) 2018-08-14
TW201406779A (zh) 2014-02-16
MY181422A (en) 2020-12-21
SG10201608378UA (en) 2016-11-29
BR112014026852A2 (pt) 2017-07-18
EP3978522A2 (en) 2022-04-06
SMT202500396T1 (it) 2025-11-10
LT2844672T (lt) 2020-04-10
ZA202202846B (en) 2023-11-29
PL2844672T3 (pl) 2020-08-10
EP3660047B1 (en) 2021-10-13
FI3978522T3 (fi) 2025-11-13
SMT202200014T1 (it) 2022-03-21
SG11201406748QA (en) 2014-11-27
US20170210790A1 (en) 2017-07-27
JP6603269B2 (ja) 2019-11-06
EP4653056A3 (en) 2026-05-13
RS62636B1 (sr) 2021-12-31
EP3978522B1 (en) 2025-10-01
LT3660047T (lt) 2021-11-10
KR20150005666A (ko) 2015-01-14
AU2018203087B9 (en) 2020-03-26
AU2013256251B2 (en) 2018-04-12
CA2871077A1 (en) 2013-11-07
LT3978522T (lt) 2025-11-25
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
BR122019023685B1 (pt) 2023-01-17
HRP20251429T1 (hr) 2026-01-02
CN110240651B (zh) 2024-03-08
CA2871077C (en) 2021-08-17
IN2014DN08767A (ar) 2015-05-22
IL235121A0 (en) 2014-12-31
US10047152B2 (en) 2018-08-14
ES2898372T3 (es) 2022-03-07
SMT202000241T1 (it) 2020-07-08
PL3978522T3 (pl) 2026-01-05
SI3978522T1 (sl) 2025-11-28
US20220025029A1 (en) 2022-01-27
HRP20211932T1 (hr) 2022-03-18
ES3049982T3 (en) 2025-12-19
HRP20200652T1 (hr) 2020-07-10
US12252530B2 (en) 2025-03-18
AU2018203087B2 (en) 2020-03-12
MY195564A (en) 2023-02-02
HK1202123A1 (en) 2015-09-18
US20150299303A1 (en) 2015-10-22
AU2013256251A1 (en) 2014-11-06
PL3660047T3 (pl) 2022-02-14
ZA201407302B (en) 2021-08-25
AU2013256251C1 (en) 2018-08-23
HUE049440T2 (hu) 2020-09-28
UY34782A (es) 2013-11-29
NZ733480A (en) 2019-03-29

Similar Documents

Publication Publication Date Title
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
MX2023000390A (es) Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
Bondi et al. Found in translation: understanding the biology and behavior of experimental traumatic brain injury
Terzieva et al. Early pregnancy human decidua is enriched with activated, fully differentiated and pro-inflammatory gamma/delta T cells with diverse TCR repertoires
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
PL2560993T3 (pl) Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
EP2170950A4 (en) ANTI-IL-20 ANTIBODIES AND THEIR USE IN TREATMENT OF IL-20 ASSOCIATED INFLAMMATORY DISEASES
BRPI0917470A2 (pt) anticorpos humanos que se ligam ao gene de ativação linfocitária-3(lag) e usos dos mesmos
SI2928923T1 (sl) Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d&#39;utilisation associées
TR201904882T4 (tr) Tıbbi kullanım için bispesifik antikorlar.
WO2014120975A8 (en) Antibody-mediated immunocontraception
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
EP2611928A4 (en) ANTI-C-MET ANTIBODIES AND METHOD FOR THEIR USE
AR117721A2 (es) Anticuerpos humanos para fel d1 y métodos para usarlos
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Suzuki et al. Basic and clinical immunology–3022. Inhibitory action of fexofenadine hydrochloride on mast cell activation in vitro
de León Muñoz Quality and culture of health
Grainger Immune modulation by parasitic nematodes
Autors et al. Of Bodies and Symptoms
Haapalinna The Effects of Atipamezole on Brain Neurochemistry and Behaviour in Laboratory Rodents: Possible Implications for the Treatment of Neurodegenerative Diseases with an Alpha2-adrenoceptor Antagonist
TH165236A (th) ฮิวเมนแอนติบอดีต่อ GFRalpha3 และวิธีการใช้มัน
TH156259A (th) แอนติบอดี้ชนิดต้าน asic1 และการใช้ประโยชน์ของมัน